Noemi Reguart

4.3K posts

Noemi Reguart banner
Noemi Reguart

Noemi Reguart

@NReguart

MD, PhD, Lead Thoracic Oncol. Unit @hospitalclinic, MedOnc, Prof. @unibarcelona, Researcher Transl Genom 🧬 Targeted Therapies @IDIBAPS, @EORTC @GECP_org, #LCSM

Sitges, España Katılım Mart 2017
610 Takip Edilen3.6K Takipçiler
Noemi Reguart retweetledi
Grupo Español de Cáncer de Pulmón
Grupo Español de Cáncer de Pulmón@gecp_org·
⭕ Nuevo episodio de LUNGPOD, una iniciativa del GECP en colaboración con Lilly. 🫁 En este capítulo abordamos el papel de las fusiones RET en el cáncer de pulmón no microcítico 🧑‍⚕️ Participan: ➡️ Amelia Insa, oncóloga médica del Hospital Clínico Universitario de Valencia ➡️ @Ecarcereny, oncólogo médico del ICO Badalona y vicepresidente del GECP 🙌 Un diálogo clave sobre diagnóstico molecular, biopsia líquida y terapia dirigida en oncología de precisión. 👉 Escúchalo aquí: gecp.org/episodio-12-fu…
Grupo Español de Cáncer de Pulmón tweet media
Español
0
1
2
214
Noemi Reguart retweetledi
IASLC
IASLC@IASLC·
#ASCO26 recap: Dr. Jonathan W. Goldman presents new findings from the LIBRETTO-432 trial. 🔗 Read his insights now in ILCN: bit.ly/4uCZhWX #LCSM
English
0
4
12
729
Noemi Reguart retweetledi
IASLC
IASLC@IASLC·
📣 The IASLC Women in #ThoracicOncology Task Force survey is still open. If you're a woman working in thoracic oncology, we want to hear about your experiences, perspectives, and priorities. Your feedback will help guide future initiatives to support women across the field. Take the survey: bit.ly/4uAPNwd #WomenInMedicine
IASLC tweet media
English
1
10
15
1.5K
Noemi Reguart retweetledi
IASLC
IASLC@IASLC·
What can attendees expect at the IASLC 2026 World Conference on Lung Cancer (#WCLC26)? @StephenVLiu and @NarjustFlorezMD are joined by Drs. Myung-Ju Ahn, Vincent Wentao Fang, Jiraporn Setakornnukul, and Yasushi Yatabe for a preview of WCLC26, taking place September 12–15 in Seoul, Republic of Korea. Hear about key deadlines, program highlights, scientific opportunities, and what makes WCLC the premier global meeting in thoracic oncology. 🎧 bit.ly/49R0gLG #LungCancer #LungCancerConsidered #ThoracicOncology #Conference
IASLC tweet media
English
0
12
29
1.6K
Noemi Reguart retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Analysis using Korean insurance claims data: of 10,275 pts receiving immunotherapy for NSCLC, 7.6% complete planned 2y - no significant difference with various agents. Note that after 3y off therapy, 42% of pts received subsequent treatment. lungcancerjournal.info/article/S0169-…
Stephen V Liu, MD tweet media
English
3
19
51
5.9K
Noemi Reguart retweetledi
IASLC
IASLC@IASLC·
🎧 In Part 2 of the #ASCO26 Highlights series, @NarjustFlorezMD and @StephenVLiu are joined by Dr. Julie R. Brahmer and @peters_solange to discuss key immunotherapy advances presented at the 2026 @ASCO Annual Meeting. The episode covers emerging data on PD-1/VEGF and PD-L1/VEGF bispecific antibodies, ADC-immunotherapy combinations, and promising new strategies for #KRAS-mutant lung cancers. Listen now : bit.ly/4uZjt6o #LungCancer #LungCancerConsidered
English
0
10
22
2.1K
Noemi Reguart retweetledi
Stephen V Liu, MD
Stephen V Liu, MD@StephenVLiu·
Details on safety of consolidation osimertinib after chemoradiation for EGFR mutant NSCLC from the phase III LAURA trial. Radiation pneumonitis seen in 48% with osi and 38% with placebo, mostly low grade, 87% continued osi, 93% without recurrence. lungcancerjournal.info/article/S0169-…
English
2
17
45
4.1K
Noemi Reguart retweetledi
Giannis Mountzios
Giannis Mountzios@g_mountzios·
A pleasure to present for @PeerView , with my colleague @nicogirardcurie , the aspects of identifying, managing and monitoring the special adverse effects of treatment with DLL3-targeting T-cell engagers: ▶️ CRS ▶️ ICANS ▶️ ILD Link to the webcast:📌 peervoice.com/KDZ
Giannis Mountzios tweet media
English
1
1
14
1K
Noemi Reguart retweetledi
Hidehito HORINOUCHI
Hidehito HORINOUCHI@HHorinouchi·
🔥Phase 1: ABBV-706 (SEZ6-targeting ADC) in R/R SCLC & solid tumors 🆙 @NatureMedicine ☑R/R SCLC; ORR 52%; mOS 12.4 mo at RP2D 🎯RP2D confirmed at 1.8 mg/kg Q3W balancing efficacy & safety 🎙 @LaurenByersMD #LCSM @OncoAlert @Larvol nature.com/articles/s4159…
Hidehito HORINOUCHI@HHorinouchi

🔁REVIEW #ASCO26 #LCSM Oral 🔥ABBV-706 (SEZ6-ADC) ± Budigalimab in relapsed/refractory SCLC ✅Mono 1.8mg/kg 2L: mOS 14.3m, 15m OS 50% ✅Overall: mOS 11.3m, 15-m OS 40% 🎙️ @LaurenByersMD 🔢8008 ☑️NCT05599984 🔗 asco.org/abstracts-pres… @OncoAlert @Larvol @ASCO @IASLC

English
1
8
19
3.3K
Noemi Reguart retweetledi
Meritxell Mollà
Meritxell Mollà@MeritxellMolla·
🔝Expanding indications of SBRT as a RadicalTreatment 🎯Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study - The Lancet Oncology thelancet.com/journals/lanon…
English
0
1
2
232
Noemi Reguart retweetledi
Dr. Estela Rodriguez
Dr. Estela Rodriguez@Latinamd·
🔥🔥 off the press and including latest #ASCO26 data: @ASCO Updated #LivingGuidelines for #LungCancer with driver alterations adds: 1️⃣ EGFR lung cancer 1L - combination tx preferred, osimertinib as alternative 2️⃣EGFR atypical ( G719X, L861Q, S7681) amivantamab +lazertinib fist line added based on #CHRYSALLIS2 @EGFRResisters #lcsm
ASCO@ASCO

Our new living guideline Therapy for Stage IV NSCLC With Driver Alterations emphasizes broad NGS & IHC (PD-L1, HER2, MET) prior to frontline therapy. Comprehensive profiling is linked to ⬆️ OS & cost-effectiveness in Stage IV NSCLC: bit.ly/4wHjjSf #LungCancer #NSCLC

English
1
13
31
3.7K
Noemi Reguart retweetledi
Sanjay Popat
Sanjay Popat@DrSanjayPopat·
Important data.
Lung Cancer Europe@LungCancerEu

‼️ Landmark #lungcancer research published today in Cell Scientists at the Francis Crick Institute and UCL have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis, works in never-smokers, and could identify who benefits from prevention treatment. People with high levels of these proteins were the ones who actually benefited from a drug to damp that inflammation down, cutting their lung cancer risk nearly in half. This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk. doi.org/10.1016/j.cell… #LCSM

Català
0
11
27
4K
Noemi Reguart retweetledi
Rami Manochakian MD, FASCO Cancer Education
Rami Manochakian MD, FASCO Cancer Education@RManochakian·
🔥🚨1/2 @OncoAlert Hot off the press. ⭐️My co-authors & I are excited & proud to share this, JUST PUBLISHED, #Manuscript in the 2026 #ASCOEdBook in conjunction with #EducationSession Presentation at #ASCO26 @ASCO👇🏻 ❇️“#Updates in #SmallCell #LungCancer-NO LONGER TOO SMAL to Ignore. A #Review of Recent #Therapeutic #Advances.” 👇🏻 ascopubs.org/doi/10.1200/ED…
Rami Manochakian MD, FASCO Cancer Education tweet mediaRami Manochakian MD, FASCO Cancer Education tweet mediaRami Manochakian MD, FASCO Cancer Education tweet mediaRami Manochakian MD, FASCO Cancer Education tweet media
English
5
30
83
5.2K
Noemi Reguart retweetledi
JTO & JTO CRR
JTO & JTO CRR@JTOonline·
Deulorlatinib demonstrated encouraging anti-tumor activity in patients with advanced ALK-positive NSCLC after failure of second-generation ALK inhibitors, including those with the G1202R mutation. 📑Read more here: bit.ly/4x1sqNH
JTO & JTO CRR tweet media
English
0
2
6
403

Keşfet

@Cancer_Cell @OncoAlert @Larvol @EGFRResisters @Ecarcereny @DrAlexAdjei @TommyJohn00 @StephenVLiu